Biotech developing therapies targeting fibrosis and Crohn's disease.
Founders
Paolo Michieli(Italy · ♂)— His two-decade University of Turin research on hepatocyte growth factor (HGF) for tissue regeneration formed the scientific foundation on which AgomAb Therapeutics was built.
Tim Knotnerus(Netherlands · ♂)— He supported AgomAb from 2017 and joined as CEO in early 2019, leading the company that commercializes Michieli's regenerative-antibody science.
Members see the full profile
Create a free EquityFlow account to see AgomAb Therapeutics's 1 funding round, 4 investors, 12 similar companies.